Zolgensma, a new drug approved by the FDA Friday, costs more than $2.1 million.

It’s made by AveXis, a drugmaker owned by pharmaceutical giant Novartis. The federal Food and Drug Administration has approved gene therapy for a rare childhood disorder that is now the most expensive drug on the market. It costs $2.125 million per patient. Novartis set the price at $2.125 million but offers insurers the ability to pay $425,000 a year for five years. This price tag makes Zolgensma the most expensive drug ever approved.

And now, the DICHOTOMY!

Novartis CEO Vas Narasimhan navigated through a tough and transitional year at the drugmaker, racking up almost $10 million in salary, incentive pay and equity awards for his efforts. But his 2018 take-home pay took a hit on longer-term shareholder returns that weren’t up to par.

The top executive’s pay didn’t suffer, however, from a painful political scandal stemming from a consulting agreement with President Trump’s personal lawyer Michael Cohen—even though Novartis’ societal trust accounts for 8% of his target bonus.

After officially taking the helm on Feb. 1, Novartis awarded Narasimhan 9.92 million Swiss francs ($9.89 million) in compensation at grant value in 2018, according to a company filing with the U.S. Securities and Exchange Commission. That’s quite a bit less than former CEO Joe Jimenez racked up in 2017 after eight years at the helm: CHF 13.10 million ($13.05 million) in total.

Get to your own conclusions!

Call Now Button